This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.
申请公布号
WO2004064764(A3)
申请公布日期
2005.01.13
申请号
WO2004US00175
申请日期
2004.01.06
申请人
SYNAPTIC PHARMACEUTICAL CORPORATION;MARZABADI, MOHAMMAD, R.;WETZEL, JOHN, M.;CHEN, CHIEN-AN;JIANG, YU;LU, KAI
发明人
MARZABADI, MOHAMMAD, R.;WETZEL, JOHN, M.;CHEN, CHIEN-AN;JIANG, YU;LU, KAI